VIRX (Viracta Therapeutics) 3-1 Month Momentum %: N/A% (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Viracta Therapeutics 3-1 Month Momentum %?

Viracta Therapeutics VIRX 3-1 Month Momentum % is N/A% as of Aug. 23, 2026.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-23), Viracta Therapeutics's 3-1 Month Momentum % is N/A%.

The industry rank for Viracta Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

VIRX's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.29
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Viracta Therapeutics  (OTCPK:VIRX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Viracta Therapeutics 3-1 Month Momentum % Related Terms

VIRX vs TSOI, CYTOF, TRVN: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Viracta Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's 3-1 Month Momentum % falls into.


Viracta Therapeutics  (OTCPK:VIRX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Viracta Therapeutics (VIRX) has a 3-1 Month Momentum % of N/A% as of Aug. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' 3-1 Month Momentum % too high?
Viracta Therapeutics' current 3-1 Month Momentum % is N/A%.
How does Viracta Therapeutics' 3-1 Month Momentum % compare to TSOI and CYTOF?
Viracta Therapeutics' 3-1 Month Momentum % of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current 3-1 Month Momentum % is N/A% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.